Prophylactic Management of Radiation-Induced Nausea and Vomiting

Table 4

Randomised clinical trials with 5-HT₃ RAs in patients undergoing TBI and HBI adapted from [1].

Study		Radiotherapy regimens	Antiemetic treatment	CR; (% of patients)	Result
Grant Prentice et al. (1995) [11]	30	7.5 Gy; TBI single fraction	GRAN 3 mg i.v.; versus; MCP 20 mg i.v. + DEX 6 mg/m^2 i.v. + LOR 2 mg i.v.	53; 13	GRAN better than MCP + DEX + LOR
Tiley et al. (1992) [42]	20	10.5 Gy; TBI single fraction	OND 8 mg i.v.; Placebo	90^a; 50^a	OND better than placebo
Spitzer et al. (1994) [43]	20	1.2 Gy 3/day; TBI 11 fractions to a total dose of 13.2 Gy	OND 8 mg 3/day p.o.; Placebo	50; 0	OND better than placebo
Sykes et al. (1997) [44]	66	8–12.5 Gy; HBI single fraction	OND 8 mg 2 p.o.; versus; CLP 25 mg 3 p.o. + DEX 6 mg 3 p.o.	34	OND better than CLP + DEX
Huang et al. (1995) [45]	116	7–7.7 Gy	OND 8 mg i.v. + DEX 10 mg; versus; MCP 10 mg + DEX 10 mg	84; 20	OND + DEX better than paspertin + DEX
Spitzer et al. (2000) [13]	34	1.2 Gy 3/day; TBI 11 fractions to a total dose of 13.2 Gy	OND 8 mg 3/day p.o.; versus; GRAN 2 mg 1/day p.o.	47; 61	No difference

All patients received i.v. dexamethasone (8 mg) and phenobarbitone (60 mg/m²).
CLP = chlorpromazine; CR = complete response; DEX = dexamethasone; GRAN = granisetron; HBI = half-body irradiation; LOR = lorazepam; MCP = metoclopramide; OND = ondansetron; TBI = total-body irradiation; p.o. = orally; i.v. = intravenously.